Trials / Completed
CompletedNCT05221580
China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)
A Prospective Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in China
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 887 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect information on how Ryzodeg® works in real-world patients. Participants will get Ryzodeg® as prescribed to by their doctor. The study will last for about 5-8 months. Participants will be asked questions about their health and their diabetes treatment as part of their normal doctor's appointment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ryzodeg® | Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician |
Timeline
- Start date
- 2022-03-18
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
- First posted
- 2022-02-03
- Last updated
- 2024-06-14
Locations
50 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05221580. Inclusion in this directory is not an endorsement.